People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...

Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

Opens in a new tab or window Share on Bluesky ... The cohort comprised adults age 40 and older with type 2 diabetes who initiated treatment with an SGLT2 inhibitor, DPP-4 inhibitor, or GLP ...

According to the study, cannabinoids showed stronger binding affinities to these enzymes compared to some standard diabetes drugs, with the exception of DPP-4 inhibitors. THC and CBN demonstrated ...

Health experts are investigating a possible link between popular weight loss drugs like Ozempic and sudden blindness.